Related references
Note: Only part of the references are listed.Biochemical characterization of cholesteryl ester transfer protein inhibitors
Mollie Ranalletta et al.
JOURNAL OF LIPID RESEARCH (2010)
Modulating cholesteryl ester transfer protein activity maintains efficient pre-β-HDL formation and increases reverse cholesterol transport
Eric J. Niesor et al.
JOURNAL OF LIPID RESEARCH (2010)
Safety of Anacetrapib in Patients with or at High Risk for Coronary Heart Disease.
Christopher P. Cannon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Lessons Learned from the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) Trial
Philip Barter
AMERICAN JOURNAL OF CARDIOLOGY (2009)
Single-dose pharmacokinetics and pharmacodynamics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects
Rajesh Krishna et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2009)
The metabolism and anti-atherogenic properties of HDL
Kerry-Anne Rye et al.
JOURNAL OF LIPID RESEARCH (2009)
Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone
M. J. Forrest et al.
BRITISH JOURNAL OF PHARMACOLOGY (2008)
Cholesteryl Ester Transfer Protein Inhibition, High-Density Lipoprotein Raising, and Progression of Coronary Atherosclerosis Insights From ILLUSTRATE (Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosclerosis by CETP Inhibition and HDL Elevation)
Stephen J. Nicholls et al.
CIRCULATION (2008)
Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk
Alexander Thompson et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2008)
Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies
Rajesh Krishna et al.
LANCET (2007)
Effects of torcetrapib in patients at high risk for coronary events
Philip J. Barter et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Inhibition of CETP activity by torcetrapib reduces susceptibility to diet-induced atherosclerosis in New Zealand White rabbits
Lee A. Morehouse et al.
JOURNAL OF LIPID RESEARCH (2007)
Antioxidant and cytoprotective properties of high-density lipoproteins in vascular cells
Anne Negre-Salvayre et al.
FREE RADICAL BIOLOGY AND MEDICINE (2006)
Endothelial and antithrombotic actions of HDL
Chieko Mineo et al.
CIRCULATION RESEARCH (2006)
Description of the torcetrapib series of cholesteryl ester transfer protein inhibitors, including mechanism of action
RW Clark et al.
JOURNAL OF LIPID RESEARCH (2006)
New insights into the regulation of HDL metabolism and reverse cholesterol transport
GF Lewis et al.
CIRCULATION RESEARCH (2005)
Effectiveness of inhibition of cholesteryl ester transfer protein by JTT-705 in combination with Pravastatin in type II dyslipidemia
JA Kuivenhoven et al.
AMERICAN JOURNAL OF CARDIOLOGY (2005)
Consequences of cholesteryl ester transfer protein inhibition in patients with familial hypoalphalipoproteinemia
RJ Bisoendial et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2005)
Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol
ME Brousseau et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: An initial multidose study of torcetrapib
RW Clark et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2004)
Natural genetic variation as a tool in understanding the role of CETP in lipid levels and disease
SM Boekholdt et al.
JOURNAL OF LIPID RESEARCH (2003)
Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans - A randomized phase II dose-response study
GJ de Grooth et al.
CIRCULATION (2002)
A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits
H Okamoto et al.
NATURE (2000)
1999 George Lyman Duff Memorial Lecture - Lipid transfer proteins, HDL metabolism, and atherogenesis
AR Tall et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2000)
Vaccine-induced antibodies inhibit CETP activity in vivo and reduce aortic lesions in a rabbit model of atherosclerosis
CW Rittershaus et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2000)
Share Paper
